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PURPOSE. To evaluate the therapeutic potential of the small molecule integrin a5b1 inhibitor,
CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose
regimens and administration routes of the inhibitor were compared with mitomycin C
(MMC), the gold standard in clin ical practice.
METHODS. The efficacy of CLT-28643 on surgical outcome was studied in a mouse model for
filtering surgery (n ¼ 40 eyes from 20 mice per group). Single and repeated subconjunctival
(SCJ) injections (1 or 2 lg) and topical eye drops (10 lg) of the integrin inhibitor were
compared with 2-minute administration of MMC 0.02%. Bleb size, survival, and signs of
toxicity were examined until 28 days after surgery. Immunohistochemical analysis of
angiogenesis, inflammation, collagen deposition, and integrin a5b1 expression were
performed on postoperative days 3, 8, 14, and 28. A masked observer performed all the
assessments.
RESULTS. Immunostaining showed that integrin a5b1 was highly expressed in the bleb at early
time-points after surgery and that CLT-28643 inhibited this upregulation. Efficacy was shown
to be dose-dependent for the integrin inhibitor CLT-28643 for bleb area and survival, and the
wound healing process. While 2-lg single injection of CLT-28643 improved bleb
characteristics in a similar way as 10-lg administered by eye drops and MMC, repeated
injections of 2 lg showed superior efficacy compared to MMC, with no corneal toxicity.
CONCLUSIONS. Administration of the integrin a5b1 inhibitor CLT-28643 has therapeutic
potential as an adjunct to glaucoma surgery, possibly with a superior efficacy and tolerability
compared with MMC when used at the optimal dose.
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The importance of fibrosis in various pathologic processes inthe eye is known. With respect to glaucoma surgery,
success depends on the correct balance between adequate
wound healing and maintaining a functioning fistula. Surgery
immediately triggers a series of cellular and extracellular
cascades to promote the wound healing process.1 Several cell
types are involved with interaction with other cell types and
various membrane proteins by means of cell surface inte-
grins.2,3 Integrins constitute an important class of transmem-
brane receptors responsible not only for cell–cell adhesion, but
also for cell–extracellular matrix (ECM) interaction.4 Among
these is integrin a5b1, a well-characterized fibronectin recep-
tor, and known to be an important player in angiogenesis
within several organs, including the eye. The a5 subunit is
found only in combination with b1 and this determines its
receptor activity.5
Fibronectin is a major component of ECM and binds to a
number of integrins mostly through its arginine-glycine-aspartic
acid (RGD). Integrin a5b1 is probably the major fibronectin
receptor in most tissues.5 The knockout of the a5 subunit in
mice resulted in nearly the same defects as the fibronectin-null
mutation,5,6 suggesting that most of the effects of fibronectin
result from its binding to integrin a5b1. In quiescent cells,
integrin a5b1 is absent or inactive. In many pathologic and
some physiological processes requiring the proliferation and
migration of cells, integrin a5b1 becomes upregulated and
activated. The activated integrin-fibronectin complex is in-
volved in many processes, such as angiogenesis,7 inflamma-
tion,8,9 wound healing,2 and contributes to many diseases, for
example, psoriasis10 and cancer.11–13 In angiogenesis, integrin
a5b1 binding to ECM regulates the proliferation, motility, and
survival of endothelial cells14 and antibodies and other
inhibitors of integrin a5b1 have an antiangiogenic effect.15–17
Integrin a5b1 is also involved in the interaction between
fibroblast and ECM. In vitro data have shown the upregulation
of integrin a5b1 expression after stimulation of fibroblast or
other myofibroblast precursor-cells with the profibrotic growth
factor TGF-b, platelet-derived growth factor (PDGF), connective
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tissue growth factor (CTGF), as well as the promotion of
fibrotic differentiation by fibronectin.18–21 The important role
of integrin a5b1 in fibrosis was also shown in vivo in kidney,
lung, liver, and skin fibrosis models.22–26
Moreover, Zahn et al.27 showed that the integrin a5b1-
fibronectin interaction is a promising target for the treatment
of fibrotic and inflammatory processes in the eye such as
proliferative vitreoretinopathy (PVR). In another study, the
administration of nonpeptidic analogues of the RGD sequence
specifically inhibited the adhesion of human Tenon’s capsule
fibroblasts to fibronectin in culture.28 Furthermore, the benefit
of nonspecific integrin inhibition in glaucoma surgery was
shown by the positive effect of RGD peptides in improvement
of the surgical outcome in rabbit.29,30 Importantly, the specific
role of integrin a5b1 in the postoperative process of wound
healing is not fully understood. These findings, however,
suggest that integrin a5b1 might be a therapeutic target to
prevent filtration failure after glaucoma surgery, because
excessive postoperative wound healing of the conjunctiva
and Tenon’s capsule, with subsequent scarring, frequently
leads to surgical failure.31 In the present study, we demon-
strated the expression and the time course of integrin a5b1 in
the bleb following glaucoma surgery in a mouse model. The
same model was subsequently used to investigate different
dose regimens of a novel integrin a5b1 inhibitor, CLT-28643,
and compared with the current standard of care, mitomycin C
(MMC).
CLT-28643 is a novel small molecule with specific integrin
a5b1 inhibiting properties. It inhibits RGD-induced conforma-
tional changes of integrin a5b1 to prevent integrin a5b1-
fibronectin interaction. In in vivo studies in xeno- and syno-
graft tumor models, CLT-28643 inhibited tumor growth and
angiogenesis.32 The inhibition of fibrosis and inflammation of
CLT-28643 was shown in a bleomycin-induced lung fibrosis
model.33
MATERIALS AND METHODS
Mouse Model of Glaucoma Filtration Surgery
In this study, C57BL/6J mice (8- to 10-weeks old; Charles River
Laboratories, Lyon, France) were used in accordance with the
standards in the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The Institutional Animal Care
and Research Advisory Committee of KU Leuven approved all
experimental animal procedures (P084/2014).
All mice were anesthetized with an intraperitoneal injection
of 103 diluted (60 mg/kg final dose) sodium pentobarbital
(Nembutal, 60 mg/mL; CEVA, Sante Animale, Brussels,
Belgium). Filtering surgery was performed on both eyes, using
a technique that has been described previously and that results
in a filtering bleb.34–36 Briefly, the conjunctiva was first
surgically dissected to expose the underlying sclera and a
small filtration subconjunctival space was created by running
the surgical scissors underneath the dissected conjunctiva.
Next, a 30-G needle was used to make an incision through the
sclera into the anterior chamber of the eye to allow aqueous
humor to escape into the subconjunctival space. Finally, the
conjunctiva was closed at the limbus by suturing over the
newly-created fistula (using a 10-0 nylon suture; Alcon,
Vilvoorde, Belgium). Tobradex ointment (SA Alcon-Couvreur,
Vilvoorde, Belgium) was applied at the end of the procedure.
Treatment Scheme
In a first experiment, five mice (10 eyes) per time-point were
used to evaluate integrin a5b1 expression in the bleb on
postoperative days 3, 8, 14, and 28 by immunohistochemistry
(see section Immunohistologic Investigation). In a second
experiment, 120 mice were divided in 6 groups of 20 mice
each (40 eyes/group) in order to investigate the in vivo efficacy
of CLT-28643 on bleb characteristics and compare its effects
with MMC. An overview of the different groups is given in
Table 1. For study medication, ready-to-use formulations of
vehicle and integrin inhibitor, small molecule CLT-28643 (0.2%;
provided by Clanotech AB, Stockholm, Sweden), were used. In
groups 1, 4, and 5, repeated subconjunctival (SCJ) injections (1
lL) of vehicle or CLT-28643 (2 or 1 lg), respectively, were
given on days 0, 3, 7, 14, and 21 after surgery. In group 2,
surgical sponges soaked with MMC (0.02%) were placed on the
exposed sclera for 2 minutes before creating the channel. After
removing the sponge, the ocular tissue was extensively rinsed
with 2 mL of NaCl. In group 3, single injection (1 lL; 2 lg) of
the integrin inhibitor was administered immediately after
surgery. Group 6 was treated with CLT-28643 drops (5 lL, 10
lg) 33 daily until killed. All injections were performed in both
eyes by using an analytic science syringe (SGE Analytic Science,
Victoria, Australia) and glass capillaries with a diameter of 50 to
70 lm at the end, controlled by the UMP3I Microsyringe
Injector and Micro4 Controller (all from World Precision
Instruments, Inc., Hertfordshire, UK).
Clinical Investigation
Mice were clinically examined on day 1 after surgery and then
every 2 days until they were killed. Bleb area and bleb survival
were analyzed under topical anesthesia (Unicain, The´a Pharma,
France). Commercial software (KS300; Zeiss, Brussels, Bel-
gium) was used to determine the bleb size from bleb images of
mice. More information on the measurement of the bleb area is
provided in the Supplementary Material. These pictures were
taken using a digital camera (Canon PowerShot S50; Canon,
Brussels, Belgium) using a 33 optical zoom lens at a
magnification of 34. Of note, pictures were taken before
repeated administration of the compound, when the two
procedures took place on the same day. The boundaries of the
bleb on the images were defined based on the appearance of
the conjunctiva. Whitish conjunctiva indicates that the
conjunctiva was separated from the sclera and was filled with
fluid. On the other hand, a bluish/grayish conjunctiva indicates
that the conjunctiva was attached to the sclera without any
TABLE 1. Overview of Different Treatment Groups
Group, n ¼ 120 Mice Compound Dose Administration
Group 1, n ¼ 20 Vehicle NA SCJ injections D0, 3, 7, 14, and 21
Group 2, n ¼ 20 MMC 0.02% 2-min sponge application þ 2 mL rinse NaCl
Group 3, n ¼ 20 CLT-28643 2 lg SCJ injection D0
Group 4, n ¼ 20 CLT-28643 2 lg SCJ injections D0, 3, 7, 14, and 21
Group 5, n ¼ 20 CLT-28643 1 lg SCJ injections D0, 3, 7, 14, and 21
Group 6, n ¼ 20 CLT-28643 10 lg 33 drops daily
SCJ, subconjunctival; D, day; NA, not applicable.
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fluid between the two layers (Supplementary Fig. S1A). Bleb
survival was taken as the end-point of the study, while bleb
failure was defined as the appearance of a scarred and flat bleb
on two consecutive measurements.34 Failure of the bleb was
recorded at the second measurement. Also, corneal opacity
was graded on these pictures at days 1, 3, 5, 7, 13, 21, and 27
after surgery, using a previously published scoring system,37,38
ranging from 0 for a clear/transparent cornea to 4 for complete
corneal opacity. Figure 1 shows representative pictures of the
different scores of corneal opacities. The examiner of the mice
was masked to the treatment allocation for all analyses. At the
end of the study, all images were randomized and the analysis
was performed on the pictures in a masked observatory way,
all by one blinded observer. Mice were also checked for pain-
distress every other day and body weight was measured on day
0 before surgery and every week until killed.
Immunohistologic Investigation
On postoperative days 3, 8, 14, and 28 after surgery, mice were
killed by cervical dislocation (5 mice [10 eyes]/group/time
point). Both eyes were enucleated and whole eyes were fixed
in 1% paraformaldehyde overnight and rinsed three times for 5
minutes in PBS. The tissues were then dehydrated overnight in
the Shandon Excelsior ES (Thermo Fisher Scientific, Waltham,
MA, USA) and embedded in paraffin, all eyes in the same
orientation. Serial sagittal sections were cut at 7-lm thickness
on five series of five glass slides (total number of slides per eye
is 25). Hematoxylin and eosin (H&E) staining was performed
on the first slide of each series (slide 1, 6, 11, 16, and 21) to
localize the bleb on the various sections (see section ‘Imaging
and Analysis’). The consecutive slides were used for the other
immunohistologic staining. To investigate integrin a5b1
expression, an integrin staining was performed using rabbit
anti-mouse integrin antibody (1/200, AB1928; Millipore, Over-
ijse, Belgium). Slides without primary antibody were used as a
negative control and the cornea was used as a positive control,
because it is known that integrin a5 is expressed in the normal
cornea.39,40 Inflammation was analyzed by a CD45 staining as
previously described by our research group,34 and a CD31
staining was performed to visualize the blood vessels. The eye
sections were incubated overnight with rat anti-mouse CD45
antibody (1/100, 553076; Pharmingen, Erembodegem, Bel-
gium) or rat anti-mouse CD31 (1/500, 557355; Pharmingen),
respectively. The following day, the bound antibodies were
visualized using the Perkin Elmer kit (Renaissance TSA Indirect,
NEL704A; Waltham, MA, USA) and with cyanin 3 as fluoro-
phore. Deposition of collagen was analyzed in all groups by
Sirius Red staining.
Imaging and Analysis
Images were obtained using a microscope (Leica Microsystems,
Wetzlar, Germany), equipped with a digital camera (Axiocam
MrC5; Carl Zeiss, Meditec, Jena, Germany), at a magnification
of320 and a resolution of 25843 1936 pixels. Morphometric
analyses were performed based on literature,34 using commer-
cial software (KS300; Zeiss). As described above, H&E staining
was performed on the first slide of each series to localize the
bleb on the various sections. Morphologic borders on the H&E
staining were used to delineate and localize the filtrating blebs
(Supplementary Fig. S1B). The localization of a failed bleb was
defined by the scar tissue present between the conjunctiva/
sclera. After localizing the bleb on the H&E sections, adjacent
sections present on the slides within the same series, were
used to perform the different (immuno) histologic stains. For
each bleb, the middle on the H&E section was first defined,
based on the sections including a bleb. Analysis of the different
processes of wound healing was only performed in the bleb (5
sections in the middle of each filtration bleb, unless the bleb
covered fewer sections) and was calculated as a proportion of
the total bleb area. The area of the analyzed sections was
averaged to provide one value per eye. Integrin expression was
determined by calculating the integrin-positive area as a
proportion of the total bleb area on 10 slides per time point
(5 sections per slide). The density of blood vessels and
leukocytes was determined by calculating the CD31-positive
and the CD45-positive area as a proportion of the bleb area.
Deposition of collagen was determined by measuring the
percentage of the collagen positive area in the bleb area.
Polarized light was used to distinguish mature from immature
collagen fibers. Mature collagen fibers appear bright yellow or
orange, whereas immature collagen fibers appear green.
Statistical Analysis
All histologic data were analyzed using the Student’s t-test for
independent samples. Data at individual time-points were
analyzed using mixed-model analysis for repeated measures
and overall P values were calculated (GraphPad Prism 5;
GraphPad Software, San Diego, CA, USA). Kaplan-Meier
survival analysis was performed for bleb failure using the log
rank test (GraphPad Prism 5). P values less than or equal to
0.05 were considered to be statistically significant. Data are
represented as mean 6 SEM.
RESULTS
Ocular Expression of Integrin a5b1 After Glaucoma
Surgery
To investigate the localization and expression level of integrin
a5b1 in the eye and filtering bleb, immunohistochemical
staining was performed at different time-points in a mouse
model for trabeculectomy. Integrin a5b1 was not observed in
the conjunctiva of naive, nonoperated eyes but its expression
increased after filtration surgery. Integrin a5b1 was indeed
FIGURE 1. Corneal opacity grading, ranging from 0 for a clear/transparent cornea to 4 for complete corneal opacity.
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detected at every time-point assessed from day 1 to 28 after
surgery in the conjunctiva and Tenon’s capsule of the bleb (Fig.
2A). Of note, integrin a5b1 was found to be expressed in the
epithelium of the murine cornea in nonoperated eyes with an
expression pattern that was comparable to the one reported by
Zhang et al.40 (positive control, data not shown). Detailed
morphometric analysis of the integrin a5b1 labeling revealed a
peak of expression at postoperative day 3 (17.44 6 0.68%) and
a gradual decrease at later time-points (day 8: 7.81 6 0.63%
and day 14: 6.11 6 0.32 %), with almost no staining left by day
28 after surgery (1.22 6 0.19%). The expression of a5 integrin
at all time-points was significantly higher as compared with
nonoperated values (Fig. 2B; P < 0.05).
Thus, integrin a5b1 expression was found to be upregu-
lated in Tenon’s capsule and conjunctiva of the bleb after
trabeculectomy in the mouse eye. Importantly, integrin
expression was upregulated as early as day 3 after glaucoma
surgery, suggesting it might play a pivotal role during the early
stages of postoperative wound healing.
Effect of CLT-28643 on the Surgical Outcome
To determine whether inhibition of integrin a5b1 altered the
outcome of glaucoma surgery in vivo, CLT-28643 was assessed
for efficacy in preservation of the bleb in the mouse model.
Daily clinical examinations revealed that none of the animals
showed any pain-distress. No regimen-related differences in
pre- and posttreatment body weights during follow-up were
detected (data not shown).
Bleb area and survival were analyzed every 2 days after
surgery as a measure of filtration surgery outcome. Analysis of
the bleb area and survival showed that all vehicle-treated eyes
failed by day 17 (Fig. 3). All the other regimens significantly
improved bleb area and bleb survival compared with vehicle (P
< 0.05). The dose regime of repeated injections of 2 lg of CLT-
28643 was significantly superior to MMC with respect to bleb
area (P < 0.001, Fig. 3A) and both these groups showed 100%
bleb survival for the duration of the study (Fig. 3B). The effect
of a single SCJ injection of 2-lg CLT-28643 immediately after
surgery on bleb area and survival was similar to that of MMC (P
¼ 0.28, and P ¼ 0.32, respectively). Administration of 10-lg
drops of CLT-28643, 33 daily, also increased bleb area versus
vehicle and was comparable to MMC. By Day 28, 75% of the
blebs in the drops treated group failed versus MMC’s 100%
survival (P ¼ 0.003). Repeated injections of a low-dose (1 lg)
CLT-28643 was found to be less effective compared with MMC
in bleb characteristics and resulted in a significantly reduced
bleb area as compared with the antimitotic agent (P < 0.001)
and increased bleb failure (75% vs. 100%) on day 28 (P ¼
0.006). Figure 4 shows representative photographs of the blebs
after treatment on different postoperative days. Repeated
injections of CLT-28643 were clearly associated with a large
FIGURE 2. Quantification of integrin a5b1 in the bleb after glaucoma filtration surgery. (A) Images of integrin a5b1 immunolabeling in blebs at
different time-points after surgery. In naive eyes (no surgery), integrin a5b1 was expressed in the Tenon and conjunctiva (Panel 1). At days 3, 8, 14
(and 28), integrin a5b1 was clearly expressed in the bleb (Panels 2–5). Edges of the blebs are marked by a dotted line, and ocular structures such as
sclera, choroid, retina, and ciliare body (cil bod) are labeled. (B) Integrin a5b1 protein showed a peak of expression at postoperative day 3 and
gradually decreased at later time-points. The expression of integrin a5b1 at all time-points was statistically significant compared with nonoperated
levels (n ¼ 10 eyes/time point; P < 0.05).
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bleb compared with the flat and scarred blebs observed in the
respective vehicle control group. Importantly, grading corneal
opacity indicated that 2-minute administration of 0.02% MMC
significantly increased corneal toxicity as compared with
vehicle (P < 0.001), whereas treatment with CLT-28643 was
similar to vehicle (P > 0.05; Table 2). While all groups showed
some transient corneal opacification postoperatively, 8/40 eyes
(20%) of MMC-treated eyes had scores of greater than or equal
to 1.0 compared with 3/200 eyes in other treatment groups.
Thus, our data revealed a dose-dependent effect in the
efficacy of the integrin inhibitor CLT-28643. While a 2-lg single
injection of CLT-28643 improved bleb characteristics in a
similar way as 10-lg topical administration and MMC, repeated
injections of 2 lg induced an even better response in surgical
outcome, and were statistically superior to MMC in terms of
bleb area. Importantly, MMC increased corneal opacification,
to a greater extent compared with the CLT-28643- or vehicle-
treated groups.
Effect of CLT-28643 on Postoperative Wound
Healing
In order to investigate whether the improved surgical outcome
induced by CLT-28643, was associated with altered postoper-
ative healing, different immunohistologic stains for some
underlying processes were performed. Specific staining for
inflammation, angiogenesis, and collagen deposition in the
bleb were analyzed at days 3, 8, 14, and 28. Of note, in the
mouse model of glaucoma surgery, it is known that angiogen-
esis and inflammation peak early after surgery, whereas a
gradual increase in collagen deposition occurs at later time-
points.34
Inflammation
No differences in the inflammatory process were observed
between vehicle, MMC 0.02% and 1-lg repeated CLT-28643-
treated eyes at the different time-points after surgery (P >
0.05). On day 3, administration of a single 2-lg injection or 10-
lg eye drops of CLT-28643 reduced the inflammatory response
by 30% compared with vehicle treatment (P < 0.05).
Importantly, 2-lg repeated SCJ injections reduced the leuko-
cyte density by 53%, indicating that an additional reduction of
23% over a single application of CLT-28643 (P < 0.001). The
differences became less obvious after day 3, because the
leukocyte density was decreasing over time in all groups (Fig.
5).
Neovascularization
On day 3, administration of MMC, 2-lg single and repeated
injections, or 10-lg drop application of CLT-28643 decreased
the neoangiogenic process by 40%, compared with vehicle
treatment (P < 0.05). This effect was comparable to the effect
in the MMC group. Importantly, 2-lg repeated injection
induced an additional reduction in blood vessel density of
17% (total reduction of 57%) as compared with 2-lg single
integrin inhibitor injection and versus MMC (P < 0.001). Blood
vessel density in the bleb was not changed in eyes treated with
repeated low-dose injections of 1-lg CLT-28643 (P > 0.05). On
day 8, 14, and 28, MMC, 2-lg single and repeated injections
and 10-lg eye drop CLT-28643 administration still resulted in a
reduced angiogenic response compared with the vehicle group
(P < 0.05; Fig. 6).
Collagen Deposition
Analysis of the Sirius Red staining 28 days after surgery showed
that collagen deposition was significantly decreased by 31%
after MMC 0.02%, 2-lg single injection and 10-lg eye drop
treatment with the integrin inhibitor, in comparison to vehicle-
treated eyes (P < 0.05). Repeated injection of 2-lg CLT-28643
additionally reduced the fibrotic process by 21% (total
reduction of 52%), as compared with single injection of 2 lg
of the integrin inhibitor (P < 0.001). Also at days 3, 8, and 14,
CLT-28643 reduced collagen deposition, with an additional
reduction after repeated injection of 2-lg CLT-28643 on day 8
and 14, but not on day 3 (Fig. 7). Only small effects were seen
after repeated injection of 1-lg integrin inhibitor on day 8 and
14 comparison to vehicle-treated eyes (P < 0.05). Repeated 2-
lg CLT-28643 use was statistically superior to MMC on day 28
(P < 0.001).
Integrin a5b1 Expression
In order to correlate the differences in wound healing
processes after CLT-28643 treatment to a possible effect on
integrin a5b1 expression in the bleb, an immunostaining for
this transmembrane receptor was performed. Analysis on days
3, 8, 14, and 28 after surgery showed no differences in bleb
integrin a5b1 expression between vehicle, MMC 0.02%, 10-lg
drops and 1-lg repeated CLT-28643-treated eyes (P > 0.05). On
day 3, the time-point for peak of integrin expression in the
bleb, single and repeated injections of 2-lg CLT-28643 both
significantly reduced integrin expression, by 27% (P < 0.001)
and 58% (P < 0.001), respectively, as compared with vehicle
group and compared with MMC (P < 0.001). Moreover, the
effect between single and repeated injections was significantly
different (P < 0.001), indicating that 2-lg repeated injection
was able to induce an additional reduction in integrin a5b1
expression. Analysis on day 8, 14, and 28 showed similar
FIGURE 3. Clinical investigation of the bleb after administration of CLT-
28643. Bleb area (A) and bleb survival (B) after treatment with the
integrin a5b1 inhibitor (CLT-28643). Repeated injections of CLT-28643
(2 lg) were the most effective in the improvement of surgical
outcome, with superior efficacy to MMC (n ¼ 40 eyes/compound).
Arrows indicate time-points of repeated injections.
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results as compared with day 3. However, on day 14 and 28 no
additional effect was seen after 2-lg repeated injection, since
the levels of integrin expression were rather low (Fig. 8).
Overall, the results confirm that single injection of 2 lg or
topical administration (10 lg) of the integrin inhibitor result in
a comparable effect to MMC 0.02%, by almost equally
decreasing the postoperative processes of wound healing.
Importantly, repeated injection of 2 lg resulted in a more
pronounced reduction of the different wound healing process-
es, as compared with the antimitotic agent. Repeated
injections of 1 lg did not decrease inflammation or angiogen-
esis and had only a small effect on collagen deposition.
DISCUSSION
Filtration surgery remains the most effective therapy to reduce
IOP in glaucoma patients.41,42 However, this surgery frequently
FIGURE 4. Macroscopic postoperative photographs of eyes after surgery. Representative macroscopic photographs of eyes on days 1, 7, 14, and 28
show blebs. Edges of the surviving bleb are marked with a dotted line. Administration of 2 lg CLT-28643 and MMC (Panels 2–4) were clearly
associated with elevated and surviving blebs, compared with 1-lg administration (lower panels) and vehicle controls (top panels). Of note, pictures
were taken before repeated administration of the compound, when the two procedures took place on the same day.
TABLE 2. Corneal Opacity After CLT-18643 Treatment
Days After Surgery 1 3 5 7 13 21 27
Group 1: vehicle 0.20 6 0.04 0.20 6 0.04 0.17 6 0.04 0.13 6 0.04 0.10 6 0.05 0.20 6 0.08 0.20 6 0.08
Group 2: MMC 0.02%* 0.45 6 0.07 0.56 6 0.07 0.47 6 0.07 0.40 6 0.09 0.35 6 0.08 0.40 6 0.16 0.15 6 0.11
Group 3: 2 lg CLT-28643 single†‡ 0.24 6 0.04 0.21 6 0.05 0.13 6 0.04 0.10 6 0.04 0.05 6 0.03 0.00 6 0.00 0.15 6 0.11
Group 4: 2 lg CLT-28643 repeated§j j 0.19 6 0.04 0.14 6 0.04 0.13 6 0.05 0.13 6 0.05 0.08 6 0.04 0.00 6 0.00 0.00 6 0.00
Group 5: 1 lg CLT-28643 repeated¶# 0.20 6 0.04 0.16 6 0.04 0.08 6 0.03 0.03 6 0.02 0.03 6 0.03 0.00 6 0.00 0.00 6 0.00
Group 6: 10 lg CLT-28643 drops**†† 0.19 6 0.04 0.15 6 0.04 0.08 6 0.03 0.10 6 0.04 0.00 6 0.00 0.00 6 0.00 0.00 6 0.00
Scoring 6 SEM; n¼ 10 eyes/compound/time point.
* Overall P < 0.001 (vehicle vs. MMC).
† Overall P ¼ 0.96 (vehicle vs. 2 lg CLT-28643 single).
‡ Overall P ¼ 0.03 (MMC vs. 2 lg CLT-28643 single).
§ Overall P¼ 0.68 (vehicle vs. 2 lg CLT-28643 repeated [rep]).
j j Overall P ¼ 0.04 (MMC vs. 2 lg CLT-28643 rep).
¶ Overall P¼ 0.89 (vehicle vs. 1 lg CLT-28643 rep).
# Overall P¼ 0.005 (MMC vs. 1 lg CLT-28643 rep).
** Overall P¼ 0.99 (vehicle vs. 10 lg CLT-28643 drops).
†† Overall P < 0.001 (MMC vs. 10 lg CLT-28643 drops).
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fails due to subconjunctival wound healing.31 Pharmacologic
enhancement of trabeculectomy using different antiscarring
agents, such as MMC, was found to significantly improve
surgical success rate.43 However, this antimitotic agent may
result in severe side effects, such as corneal toxicity and thin-
walled avascular blebs due to its nonspecific cytotoxic effect.44
Therefore, it remains necessary to broaden the therapeutic
approach and target biologically specific and relevant path-
ways involved in scar formation.
The integrin-fibronectin complex is known to be involved
in different processes underlying wound healing, such as
inflammation, angiogenesis, and the activation of residing
fibroblasts to myofibroblasts.8,14,18,19 Cells that are activated
during wound healing, such as inflammatory, endothelial, and
fibroblasts cells can interact with each other and ECM proteins
via cell surface integrin receptors.2,3 Our data show, for the
first time, that integrin a5b1 is upregulated in Tenon’s capsule
and conjunctiva of the bleb after glaucoma surgery, with
expression levels peaking early (day 3) after surgery. These
results indicate that integrin a5b1 might be a good molecular
target for antiscarring therapy in glaucoma surgery.
Treatment with the small molecule CLT-28643, which
inhibits integrin a5b1-fibronectin interaction, indeed signifi-
cantly increased bleb area and bleb survival compared with
vehicle control and the effect correlates with the inhibition of
integrin a5b1 expression. Different dose regimen and admin-
istration routes of CLT-28643 were investigated and compared
with the gold standard in clinical practice, MMC using a mouse
model of glaucoma surgery. This mouse model is well
described and closely resembles the surgical procedure in
clinical practice performed in humans.35,36 The analysis of bleb
area and survival was performed on two-dimensional (2D) bleb
images. This read-out technique shows no difference in
measuring bleb dimensions (Supplementary Fig. S1C) com-
pared with optical coherence tomography (OCT) analysis of
the bleb35,36). Analysis showed that a single subconjunctival
injection of 2 lg or topical administration three times daily (10
lg) of CLT-28643 were comparable to MMC in surgical
outcome for 28 days after surgery. More importantly, repeated
injections of 2-lg CLT-28643 showed a statistically significant
improvement in clinical outcome compared with MMC and all
other groups.
FIGURE 5. Inflammation in the bleb after treatment with the integrin inhibitor. (A) Treatment with injection(s) of CLT-28643 (2 lg) and topical
administration significantly decreased the process of inflammation on day 3 after surgery, as compared with vehicle control (P < 0.05) and MMC
treatment (P < 0.001). Repeated injections of 2 lg induced an additional reduction (P < 0.001) and showing the highest efficacy in the reduction of
inflammation. On days 8, 14, and 28, similar observations were made after repeated administration of 2-lg CLT-28643 (n¼ 10 eyes/compound/time
point). (B) Representative pictures of the inflammation in the bleb on day 3 after surgery. The edges of the bleb are marked with a dotted line.
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The early peak of integrin a5b1 expression confirms the
prominent role of integrin a5b1 in the early phase of wound
healing after filtration surgery. This is also supported by the
strong effect of a single injection of CLT-28643, which is
comparable to the effect of MMC. Although its expression
decreases over the time, a5b1 seems to play a continued role in
the later phase of wound healing as shown by the additional
efficacy of repeated injections of CLT-28643. On the other
hand, MMC has no effect on the integrin a5b1 expression
clearly indicating that its antiscarring effect is totally different
from the targeted specific mechanism of action of CLT-28643.
Administration of CLT-28643 was nontoxic and well tolerat-
ed, whereas corneal toxicity was present after treatment with
the antimitotic agent MMC. From clinical practice, we know
that the use of MMC can be associated with various
complications related to cell toxicity, such as loss of endothelial
cells, leading to corneal opacity and swelling.45–48 Moreover,
the use of MMC can also cause changes in ocular surface,49
corneal epithelial damage,50 limbal avascularity,51 and corneal
melting.52 Thus, CLT-28643 was associated with a better safety
profile compared with MMC. These results are consistent with
previous data showing similar efficacy and safety of CLT-28643
in the rabbit model of glaucoma surgery. In a trabeculectomy-
study, 24 rabbits were included that received intraoperative
MMC application, SCJ, or topical administration on top of the
SCJ injection of CLT-28643, or placebo treatment. Clinical
investigation of the bleb showed no toxic effects after integrin
inhibition. Surgical outcome was comparable for both admin-
istration schemes of CLT-28643 and MMC and superior to
vehicle-treated control eyes.33 Other groups also reported that
peptides mimicking the RGD binding domain of fibronectin
(GGRGDSPCA) improved surgical outcome in the rabbit model
compared with saline treatment, suggesting that the integrin-
fibronectin complex plays an important role in the different
phases of wound healing.29,30 However, these peptides were
not specific for integrin a5b1.
The beneficial effect on bleb characteristics of CLT-28643
was associated with various immunohistologic changes in the
bleb after surgery. Indeed, both injection and topical admin-
istration of the inhibitor reduced the processes of inflamma-
tion, angiogenesis, and fibrosis by 20%, as compared with
vehicle-treated eyes. Single injection also reduced the integrin
FIGURE 6. Blood vessel density in the bleb after treatment with the integrin inhibitor. (A) Administration of MMC, 2-, or 10-lg application of CLT-
28643 were able to decrease the angiogenic process on postoperative day 3, in comparison to vehicle treatment (P < 0.05). Importantly, 2-lg
repeated administration induced an additional reduction in blood vessel density, compared with single treatment (P < 0.001). On days 8, 14, and 28,
MMC, 2- and 10-lg CLT-28643 administration resulted in a reduced angiogenic response in comparison to the vehicle group (n ¼ 10 eyes/
compound/time point). (B) Representative pictures of angiogenesis in the bleb on day 3 after surgery. The edges of the bleb are marked with a
dotted line.
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expression in the bleb, which can probably be explained by
the fact that preventing the integrin a5b1-fibronectin interac-
tion results in less infiltration by inflammatory cells and
reduced angiogenic sprouting and proliferation of endothelial
cells in the bleb. Surprisingly, integrin expression in the bleb
was not reduced after eye drops. These results can be
explained by the significantly lower tissue penetration after
topical administration (data not shown) and might suggest that
drops are not the most suitable way of administration. Of note,
and as already described in literature, MMC application did not
reduce bleb inflammation.53,54
Investigating the effect of repeated administration of the
integrin inhibitor, clearly demonstrated a dose-response effect
in the efficacy of the SCJ injections. Indeed, repeated
application of 1 lg was less effective compared to single 2-
lg administration and MMC in the improvement of bleb
characteristics until 28 days after surgery. Importantly for
surgical outcome, repeated injections of 2 lg CLT-28643 was
superior to 2-lg single application, with an even superior
effect compared with MMC. These results were also confirmed
by immunohistologic analysis of the blebs, showing an
additional decrease in integrin expression, inflammation,
angiogenesis, and fibrosis, as compared with single CLT-
28643 administration. Of note, the reduced integrin expression
in the bleb on day 3 after repeated 2-lg administration, as
compared with 2-lg single treatment, can be explained by the
fact that the second injection on day 3 was given a few hours
before mice were killed.
Overall, the current results indicate that by inhibiting
integrin a5b1, the small molecule, CLT-28643, affects multiple
mechanisms reducing the postoperative wound healing
process, thereby offering improved therapeutic opportunities.
We already reported improved surgical success in a rabbit
model of glaucoma surgery and in a randomized prospective
clinical trial after inhibition of VEGF. This improved surgical
outcome was associated with a reduction in angiogenesis
during the initial phase of healing and with a diminished
fibrosis in later stages. However, no effect on bleb infiltration of
inflammatory cells was observed.55,56 Since CLT-28643 has
complementary anti-inflammatory effects, it might have
therapeutic potential to be used alone or in combination with
anti-VEGF therapy. Importantly, it is known that neovascular-
FIGURE 7. Collagen deposition in the bleb after treatment with the integrin inhibitor. (A) Collagen deposition was significantly decreased after MMC
0.02%, 2- and 10-lg treatment of the integrin inhibitor at all time-points, in comparison to vehicle-treated eyes (P < 0.05). Repeated application of 2-
lg CLT-28643 additionally reduced the fibrotic process (P < 0.001) on days 8, 14, and 28, whereas lesser effects were seen after administration of 1-
lg integrin inhibitor on day 8 and 14 compared with vehicle (P < 0.05). Furthermore, on day 14 treatment with injection(s) of CLT-28643 (2 lg) and
topical administration significantly decreased the process of fibrosis compared to MMC (P < 0.001; n ¼ 10 eyes/compound/time point). (B)
Representative pictures of collagen deposition in the bleb on day 28 after surgery. The edges of the bleb are marked with a dotted line.
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ization and tumor growth are coordinated by a cross-talk
between integrin and VEGF,57,58 and the combined inhibition
of both has already been suggested in literature for cancer and
choroidal neovascularization (CNV) treatment.16,59,60
CONCLUSIONS
We showed that integrin a5b1 plays an important role in
wound healing after glaucoma filtration surgery, making it a
good target candidate in antiscarring therapy. Targeting
integrin a5b1 using the small molecule CLT-28643, seems to
possess therapeutic potential as an adjunct to glaucoma
surgery, possibly with a superior efficacy and tolerability to
MMC, when used at the optimal dose.
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